Osstem vs Straumann vs Nobel vs MIS: 2026 Compare

Dental & Cosmetic · 3 · August 2, 2025

Your dental implant brand matters more than your destination country — that's the conclusion of a 2024 meta-analysis in Clinical Oral Implants Research covering 47 studies and 28,000 implants. Here's how the four most-placed systems worldwide stack up.

Nobel Biocare: The Gold Standard

Nobel Biocare's TiUnite surface treatment has the longest clinical track record — over 25 years of published data. Their 5-year survival rate across all indications is 97.8% (Pjetursson, 2023). The NobelActive implant excels in compromised bone thanks to its aggressive thread design and condensing properties. Downsides: Nobel is consistently the most expensive option, and their proprietary prosthetic connections limit compatibility with third-party components.

Straumann BLX: Speed and Versatility

Straumann's BLX line, launched in 2019, features the Roxolid alloy (15% zirconia, 85% titanium) that's 30% stronger than pure titanium. The SLActive surface achieves osseointegration in 3-4 weeks versus the traditional 6-8 weeks. Five-year survival data from early adopters shows 97.4%. Straumann's open prosthetic platform is a major advantage — it works with most major prosthetic systems, giving patients flexibility for future maintenance regardless of location.

Osstem: South Korea's Value Leader

Osstem is the world's fourth-largest implant company and dominates the Asian market. Their TS III SA implant shows 96.2% survival at 5 years in published data — solid but a step below Nobel and Straumann. The key advantage is price: Osstem implants cost clinics 40-60% less than Nobel, and those savings typically pass through to patients. They're widely used in India, Turkey, and South Korea.

MIS Implants: The Pragmatic Choice

Israel-based MIS offers the C1 and V3 implant lines with 96.5% 5-year survival data. MIS positions itself as a 'clinician-friendly' system — intuitive surgical protocols, universal prosthetic connections, and competitive pricing. They're particularly popular in Mexico and Eastern Europe. The trade-off: less published long-term data compared to Nobel and Straumann, with most studies capping at 5-7 years.

Key Takeaways

- Nobel Biocare and Straumann lead on survival data (97.4-97.8% at 5 years)

- Osstem and MIS offer 40-60% cost savings with solid but slightly lower survival rates

- Straumann's open prosthetic platform offers the most flexibility for future care

- Always ask your clinic which brand they use — and refuse treatment if they won't disclose it

Compare real-time pricing using our global cost calculator.